Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 20/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31639329 | 0.83 | RET (0.77) | RET | |
| SCHEMBL21178939 | 0.83 | RET (0.55) | RET | |
| SCHEMBL21179080 | 0.83 | RET (0.77) | RET | |
| SCHEMBL30071117 | 0.75 | RET (0.41) | RET | |
| SCHEMBL1483040 | 0.75 | RET (0.41) | RET | |
| SCHEMBL21179089 | 0.74 | RET (0.77) | RET | |
| SCHEMBL24464378 | 0.73 | RET (0.41) | RET | |
| SCHEMBL21179096 | 0.71 | RET (0.77) | RET | |
| SCHEMBL29897217 | 0.71 | RET (0.77) | RET | |
| SCHEMBL28856912 | 0.71 | RET (0.68) | RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11472802-B2 | Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2022-10-18 | — | — | US | disclosed |
| CN-111615514-B | Substituted pyrazolo [4,3-C ] pyridine compounds as RET kinase inhibitors | 奥瑞生物药品公司 | 2022-10-11 | — | — | CN | disclosed |
| EP-3740486-A1 | SUBSTITUTED PYRAZOLYL[4,3-C]PYRIDINECOMPOUNDS AS RET KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2020-11-25 | — | — | EP | disclosed |
| US-20200339579-A1 | SUBSTITUTED PYRAZOLYL[4,3-C]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA, INC. | 2020-10-29 | — | — | US | disclosed |
| WO-2019143994-A1 | SUBSTITUTED PYRAZOLYL[4,3-C]PYRIDINECOMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2019-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200339579-A1 | SUBSTITUTED PYRAZOLYL[4,3-C]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | RET 1/4885 |
| US-11472802-B2 | Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors | RET, ROR1, BRAF | RET 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.